Regression of Dalton’s lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand
- 244 Downloads
A novel ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide (Ru(II)-CNEB) was found to interact with and inhibit M4-lactate dehydrogenase (M4-LDH), a tumor growth supportive enzyme, at the tissue level. The present article describes modulation of M4-LDH by this compound in a T-cell lymphoma (Dalton’s Lymphoma: DL) vis a vis regression of the tumor in vivo. The compound showed a dose dependent cytotoxicity to DL cells in vitro. When a non toxic dose (10 mg/kg bw i.p.) of Ru(II)-CNEB was administered to DL bearing mice, it also produced a significant decline in DL cell viability in vivo. The DL cells from Ru(II)-CNEB treated DL mice showed a significant decline in the level of M4-LDH with a concomitant release of this protein in the cell free ascitic fluid. A significant increase of nuclear DNA fragmentation in DL cells from Ru(II)-CNEB treated DL mice also coincided with the release of mitochondrial cytochrome c in those DL cells. Importantly, neither blood based biochemical markers of liver damage nor the normal patterns of LDH isozymes in other tissues were affected due to the treatment of DL mice with the compound. These results were also comparable with the effects of cisplatin (an anticancer drug) observed simultaneously on DL mice. The findings suggest that Ru(II)-CNEB is able to regress Dalton’s lymphoma in vivo via declining M4-LDH and inducing mitochondrial dysfunction–apoptosis pathway without producing any toxicity to the normal tissues.
KeywordsDalton’s lymphoma Ruthenium Ru(II)-CNEB Lactate dehydrogenase (LDH) Apoptosis Anticancer agent
This work was financially supported by a project from Department of Biotechnology (DBT), Govt. of India, (BT/PR5910/BRB/10/406/2005) sanctioned jointly to LM and SKT. The authors are thankful to UGC Centre of Advanced Studies programme to Department of Zoology, BHU, for providing infrastructural facilities. The help extended by Mr. S. Bhattacharyya, Ms. S. Srivastav, and Ms. B. Mishra is also acknowledged.
Conflict of interest
The authors declare that there are no conflicts of interest.
- 4.Keppler BK, Berger MR, Klenner T, Heim ME (1990) Metal complexes as antitumour agents. Adv Drug Res 19:243–310Google Scholar
- 18.Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613–621. doi: 10.1158/0008-5472.CAN-04-4313 CrossRefPubMedGoogle Scholar
- 20.Koukourakis M, Giatromanolaki A, Harris AL, Sivridis E (2006) Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor associated stroma. Cancer Res 66:632–637. doi: 10.1158/0008-5472.CAN-05-3260 CrossRefPubMedGoogle Scholar
- 24.Trigun SK, Koiri RK, Mishra L, Dubey S, Singh S, Pandey P (2007) Ruthenium complex as enzyme modulator: modulation of lactate dehydrogenase by a novel ruthenium(II) complex containing 4-carboxy N-ethylbenzamide as a ligand. Curr Enzym Inhib 3:243–253. doi: 10.2174/157340807781369010 CrossRefGoogle Scholar
- 26.Prasad SB, Giri A (1999) Effect of cisplatin on the lactate dehydrogenase activity and its isozyme pattern in Dalton's lymphoma bearing mice. Cytologia (Tokyo) 64:259–267Google Scholar
- 30.Pandey P, Singh SK, Trigun SK (2005) Fructose-2, 6-bisphosphate associated regulatory enzymes develop in concordance in mice brain during early postnatal life. Neurol Psychiatry Brain Res 12:69–74Google Scholar
- 31.Wang H (2000) Over expression of L-PhGPx in MCF-7 cells. In: The role of mitochondrial phospholipids hydroperoxide glutathione peroxide in cancer therapy, Ph.D. thesis, The University of Iowa, Iowa. 2000, pp 16–56Google Scholar
- 39.Stefanini M (1985) Enzymes, isozymes, and enzyme variants in the diagnosis of cancer. A short review. Cancer 55:1931–1936. doi: 10.1002/1097-0142(19850501)55:9<1931::AID-CNCR2820550917>3.0.CO;2-M CrossRefPubMedGoogle Scholar
- 46.Gaiddon C, Jeannequin P, Bischoff P, Pferrer M, Sirlin C, Loeffler JP (2005) Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J Pharmacol Exp Ther 315:1403–1411. doi: 10.1124/jpet.105.089342 CrossRefPubMedGoogle Scholar
- 49.Pederson PL (1978) Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 22:198–274Google Scholar